<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01601028</url>
  </required_header>
  <id_info>
    <org_study_id>Hydroxychloroquine</org_study_id>
    <nct_id>NCT01601028</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome</brief_title>
  <official_title>Phase 3 Study of Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Sjögren syndrome is one of the most prevalent autoimmune diseases that present with
      dry eye and dry mouth. But there is no proven effective treatment for Sjögren syndrome
      patient. The relation between toll-like receptor (TLR) and the pathogenesis of Sjögren
      syndrome has been reported. Hydroxychloroquine is TLR7 and TLR9 antagonist. A few studies
      have been reported the effectiveness of Hydroxychloroquine for Sjögren syndrome but no
      randomized controlled study has been done. So the investigators evaluate the effectiveness
      and safeness of Hydroxychloroquine for primary Sjögren syndrome by randomized controlled
      study (Hydroxychloroquine 300 mg once daily p.o. group (N = 30) versus placebo group (N =
      30).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum cytokine level</measure>
    <time_frame>16 weeks</time_frame>
    <description>IL-6, IL-17, IL-1b, TNF-alpha, INF-alpha, BAFF, etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal exam</measure>
    <time_frame>16 weeks</time_frame>
    <description>Macular exam for monitoring Hydroxychloroquine macular toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indicator of inflammation</measure>
    <time_frame>16 weeks</time_frame>
    <description>Serum ESR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear production</measure>
    <time_frame>16 weeks</time_frame>
    <description>Schirmer's test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective clinical eye complaints</measure>
    <time_frame>16 weeks</time_frame>
    <description>Ocular Surface Disease Index (OSDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear cytokine level</measure>
    <time_frame>16 weeks</time_frame>
    <description>IL-6, IL-17, IL-1b, TNF-alpha, INF-alpha, BAFF, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>16 weeks</time_frame>
    <description>Best corrected visual acuity (Snellen)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Color test</measure>
    <time_frame>16 weeks</time_frame>
    <description>HRR color vision test for monitoring hydroxychloroquine retinal toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear breakup time</measure>
    <time_frame>16 weeks</time_frame>
    <description>BUT (sec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal punctate fluorescein staining score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Corneal staining score (National Eye Institute Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum T-cell property</measure>
    <time_frame>16 weeks</time_frame>
    <description>Serum T-cell property (FACS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Autoimmune Diseases</condition>
  <condition>Sjogren's Syndrome</condition>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxychloroquine 300 mg once daily p.o.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine 300 mg once daily p.o. for 12 weeks and go off medication for 4 weeks (total 16 weeks)</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2cp/day for 12 weeks and go off medication for 4 weeks (total 16 weeks)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who is diagnosed with primary Sjögren syndrome according to American/European
             consensus group (AECG) criteria

          -  Patient with the ability to give informed, dated and signed consent before the
             beginning of any proceedings related to the trial

        Exclusion Criteria:

          -  Previous treated by Hydroxychloroquine but enough washout time after discontinuance of
             treatment, patient can be enrolled. (2 wks)

          -  Known cardiac disease, Respiratory disease, Renal disease, Gastrointestinal disease
             (except GERD)

          -  Diabetes mellitus

          -  Psoriasis

          -  Known drug allergy or hypersensitivity

          -  Previous or ongoing treatment by any drugs (include topical drug) which have effect on
             lacrimal system. But enough washout time after discontinuance of treatment, patient
             can be enrolled. (cf. SSRI, Anti-histamine, Pilocarpine, etc.)

          -  Angle closer glaucoma

          -  Patient who underwent previous intraocular surgery

          -  Macular disease

          -  Previous or ongoing treatment by drug which could have effect on macula

          -  Pregnancy

          -  Planning to get pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National Unversity Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2012</study_first_submitted>
  <study_first_submitted_qc>May 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2012</study_first_posted>
  <last_update_submitted>October 16, 2013</last_update_submitted>
  <last_update_submitted_qc>October 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>Sjogren's Syndrome</keyword>
  <keyword>Hydroxychloroquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

